Compare FNWD & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWD | CCCC |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.2M | 185.1M |
| IPO Year | 1996 | 2020 |
| Metric | FNWD | CCCC |
|---|---|---|
| Price | $36.18 | $2.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $37.50 | $12.20 |
| AVG Volume (30 Days) | 4.6K | ★ 2.2M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ 1.88 | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | $17.40 | N/A |
| Revenue Next Year | $5.44 | N/A |
| P/E Ratio | $19.31 | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $26.46 | $1.09 |
| 52 Week High | $39.99 | $3.82 |
| Indicator | FNWD | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 45.32 | 52.95 |
| Support Level | $35.25 | $2.26 |
| Resistance Level | $38.79 | $2.85 |
| Average True Range (ATR) | 0.74 | 0.20 |
| MACD | -0.16 | -0.04 |
| Stochastic Oscillator | 26.81 | 64.84 |
Finward Bancorp is a bank holding company, which engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Saving Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out through the United States.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.